French health authorities have withdrawn the medication Tavneos (avacopan) from the national market, according to reports from RTL and other French outlets. The decision comes after the drug, used to treat certain autoimmune diseases, was linked to serious side effects.
The French medicines agency (ANSM) announced the removal of the drug's marketing authorization, meaning it can no longer be prescribed or dispensed in the country. RTL reports that the withdrawal was prompted by the risk of severe adverse effects associated with the treatment.
Tavneos was approved for use in specific autoimmune conditions, which involve the immune system mistakenly attacking the body's own tissues. The drug's removal follows a review of its safety profile, which determined that the potential harms outweighed the benefits for patients.
The ANSM's announcement, as covered by Le Parisien and Sud Ouest, confirms that the drug is now considered too dangerous for continued use in France. The agency's decision affects all current prescriptions and supplies of the medication within the country.
Patients currently taking Tavneos are advised to consult their healthcare providers about alternative treatment options. The withdrawal marks a significant regulatory action, reflecting ongoing concerns about the drug's safety in real-world use.
This development highlights the continuous monitoring of approved medications and the willingness of regulators to act when new safety data emerges. The situation in France may prompt similar reviews in other countries where Tavneos is available.
